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Abstract 
Increased levels of glutamate causing excitotoxic damage accompany many 
neurological disorders. A well-characterized model of excitotoxic damage involves 
administration of kainic acid, which causes limbic seizure activity and subsequent 
neuronal death, particularly in the CA1 and CA3 areas of the hippocampus. Inhibition 
of the enzyme glycogen synthase kinase 3 (GSK-3) and cyclic AMP (cAMP) levels 
might play an important role in neuroprotection. Since intracellular cAMP levels 
depend, in part, on the activity of the phosphodiesterase enzymes (PDEs), these 
enzymes have recently emerged as potential therapeutic targets for the treatment of 
several diseases. In previous works we have shown a potent anti-inflammatory and 
neuroprotective effect of GSK-3 inhibition in a model of excitotoxicity, as well as a 
reduction of nigrostriatal dopaminergic neuronal cell death after phosphodiesterase 7 
(PDE7) inhibition, which leads to an increase in cAMP levels. The present study was 
undertaken to determine whether simultaneous inhibition of GSK-3 and PDE7 by a 
novel 5-imino-1,2,4-thiadiazole compound, named VP1.14, could prevent the massive 
neuronal loss in the hippocampus evoked by intra-hippocampal injection of kainic acid. 
Here, we show that rats treated with VP1.14 showed a reduced inflammatory response 
after kainic acid injection, and exhibited a significant reduction in pyramidal cell loss in 
the CA1 and CA3 areas of the hippocampus. Studies with hippocampal HT22 cells in 
vitro also showed a clear neuroprotective effect of VP1.14 and an anti-inflammatory 
effect shown by a decrease in the nitrite liberation and in the expression of pro-
inflammatory cytokines by primary cultures of astrocytes treated with 
lipopolysaccharide. 
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1. Introduction 
Excitotoxicity is a well-characterized mechanism of neuronal death which has been 
implicated in different brain disorders, including neurodegenerative diseases (Coyle & 
Puttfarcken 1993, Diehl et al. 1994, Doble 1999, Meldrum 2000, Nakamura & Lipton 
2010). An inflammatory response is often associated with kainic acid (KA)-induced 
hippocampal neurodegeneration. Activated glial cells increase the expression of genes 
implicated in the production of nitric oxide and proinflammatory cytokines, which in 
turn contribute to the expansion of brain injury and the increased loss of neurons 
(Oprica et al. 2003). 
 
Administration of KA into the hippocampus is a well-established model of 
excitotoxicity. KA injection is known to induce a sequence of behavioral changes, 
which are followed by neurodegeneration in specific brain regions, such as the 
hippocampus, piriform cortex, thalamus, and amygdala. A well-characterized pattern of 
neurodegeneration takes place in the hippocampus where the CA1 and CA3 pyramidal 
neurons and the interneurons of the hilus of dentate gyrus are the most vulnerable 
(Coyle 1983, Sperk 1994, Lau & Tymianski 2010). Injection of KA into rodents also 
results in the activation of glial cells and inflammatory responses typically found in 
neurodegenerative diseases. Thus, this model has been widely used to analyze the 
cellular and molecular mechanisms that underlie central nervous system injury. 
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The suppression of neuroinflammation and induction of neuroprotection by GSK-3 
inhibitors have been previously described (Luna-Medina et al. 2007a, Zhou et al. 2011). 
Moreover, GSK-3 inhibitors have been shown to possess preclinical efficacy in different 
animal models of neurodegenerative disorders, decreasing the microglial activation and 
reducing neuronal death (Martinez 2008). In fact, tideglusib, a thiadiazolidinidione GSK-3 
inhibitor, is on clinical trial phase IIb for Alzheimer’s disease (Martinez  2008, del Ser 
2010). 
Different studies have suggested that cyclic AMP (cAMP) can actively play an 
important role in neuroprotection and in the modulation of the neuroinflammatory 
response observed after a brain injury (Lonze & Ginty 2002, Volakakis et al. 2010). 
Thus, control of the levels of this nucleotide could generate the regulation of the 
pathological neuroinflammatory processes and, in consequence, the neuronal cell death 
that takes place in neurodegenerative disorders.  Moreover, cAMP may activate the 
protein kinase A (PKA) signaling pathway leading to the inactivation of GSK-3 by its 
phosphorylation at Ser9 which, as commented above, also results in neuroprotection 
(Park et al. 2010, Hayashi & Sudo 2009).   
The cellular levels of cAMP depend on their synthesis by adenyl cyclases and their 
hydrolysis by cyclic nucleotide 3’, 5’-phosphodiesterases (PDEs) (Conti & Beavo 2007, 
Mehats et al. 2002). Among the eleven families of PDEs, specifically PDE7 hydrolyzes 
cAMP and is highly expressed in the brain, being relatively abundant in the olfactory 
bulb, hippocampus, striatum and cerebellum (Miro et al. 2001, Reyes-Irisarri et al. 
2005, Sasaki et al. 2002). There is very little information regarding the physiological 
functions of PDE7. It has been suggested that this enzyme is involved in pro-
inflammatory processes and that is necessary for the induction of T-cell proliferation. 
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Very recently, our group has shown a neuroprotective effect of PDE7 inhibition in in 
vivo models of stroke and Parkinson disease. Specifically, we have demonstrated that 
S14, a heterocyclic small molecule inhibitor of PDE7 belonging to the quinazoline type 
family, conferred significant neuronal protection against different insults both in the 
human dopaminergic cell line SH-SY5Y and in primary rat mesencephalic cultures. S14 
treatment also reduced microglial activation, protected dopaminergic neurons and 
improved motor function in the lipopolysaccharide rat model of Parkinson disease 
(Morales-Garcia et al. 2011). Also, we have also shown that these quinazolines 
ameliorated brain damage and improved behavioral outcome in a cerebral artery 
occlusion stroke model (Redondo et al. 2012). 
Given the limited understanding of PDE7 involvement in brain injury, the synergy 
recently shown between the increase of cAMP and the inhibition of GSK-3 (Lipina et 
al. 2012) and our previous speculation that both enzymes could play a crucial role in 
this process, in this work we sought to address the effects of VP1.14, a 5-imino-1,2,4-
thiadiazole which inhibits both PDE7 and GSK-3 (Palomo et al. 2012),  after an 
excitotoxic injury in vivo and in vitro. Our findings demonstrate that in vivo 
administration of VP1.14 results in a reduced inflammatory response after kainic acid 
injection, and in a dramatic reduction in pyramidal cell loss in the CA1 and CA3 
subfields of the hippocampus. In addition, our in vitro studies show that VP1.14 inhibits 
inflammatory activation of primary cultures of astrocytes and rescues HT22 
hippocampal cells from an excitotoxic insult.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 The Authors Journal of Neurochemistry © 2012 International Society for 
Neurochemistry 
Materials and methods 
1.1. Animals 
All procedures with animals were specifically approved by the ‘Ethics Committee for 
Animal Experimentation’ of the Instituto de Investigaciones Biomedicas (CSIC-UAM), 
license number SAF 2010/16365, and carried out in accordance with the protocols 
issued which followed National (normative 1201/2005) and International 
recommendations (normative 86/609 from the European Communities Council). All 
efforts were made to minimize animal suffering and to reduce the number of animals 
used. Adult male Wistar rats (2-3-month old) and neonatal Wistar rats (2-day old), 
obtained from our breeding facilities (normative ES280790000188) were used 
throughout the study. 
 
1.2. Cell culture and treatments 
Rat primary astrocyte cultures were prepared from the cerebral cortex of 2-day old rats 
as described previously (Luna-Medina et al. 2005) with minor modifications. Briefly, 
after removal of the meninges the cerebral cortex was dissected, dissociated, and 
incubated with 0.25% trypsin/EDTA at 37ºC for 1 h. After centrifugation, the pellet was 
washed three times with HBSS (Gibco) and the cells were plated on poly-D-lysine (20 
μg/ml) pre-treated flasks (75 cm2). After 7-10 days the flasks were agitated in an orbital 
shaker for 4 h at 230 rpm at 37°C and non-adherent microglial cells were removed. 
Then DMEM was added to the flasks, which were agitated at 260 rpm at 37°C 
overnight. The supernatant (oligodendrocytes and some remaining microglial cells) was 
removed, and astrocytes (adherent cells) were collected. The purity of the cultures was 
> 95%, as determined by immunofluorescence analysis using mouse monoclonal anti-
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glial fibrillary acidic protein (GFAP; clone G-A-5; Sigma-Aldrich) to identify 
astrocytes.  
On attaining semiconfluence, cells were treated with VP1.14 (3 µM; MW= 580 Da.; 
GSK-3 IC50= 1.3±0.4 μM; PDE-7 IC50=0.38 μM) (Palomo et al. 2012) (Fig 1) or BRL-
50481 (30 μM, Tocris Bioscience) 2 h before exposure to glutamate (500 μM; Sigma-
Aldrich) or lipopolysaccharide (LPS, 10 µg/ml; Sigma-Aldrich) for 24 h. The 
concentration of BRL-50481 was chosen based on it effectiveness in different 
previously published works  (Morales-Garcia et al. 2011, Smith et al. 2004, Zhang et al. 
2008). Dose-response analysis and viability of VP1.14 and BRL are shown in 
Supplementary Figures 1 and 2. After treatments, cells were processed for 
immunocytochemistry, nitrite release, cell viability assay, and western blot analysis. 
 
The mouse hippocampal HT22 neuronal cell line (Invitrogen) was cultured in DMEM 
supplemented with 10% FBS and antibiotics (100 units/ml penicillin and 100 μg/ml 
streptomycin) and incubated at 37ºC under 5% CO2. To perform the experiments of cell 
viability HT22 cells were seeded onto 96-well microplates (5 000 cells/well) overnight. 
BRL-50481 (30 μM) or VP1.14 (3 µM) were added to the culture medium 2 h before 
exposure to glutamate (3 mM) and cells were incubated for 24 h before performing 
MTT assay. 
 
1.3. Intrahippocampal injections 
Adult male Wistar rats (2-3 month old) were used in this study. Rats (n ≥ 5 per group) 
were anesthetized by intraperitoneal injection of ketamine (60 mg/kg) and 
medetomidine (0.4 mg/kg) and placed into a stereotaxic apparatus (David Kopf 
Instruments, Tujunga, CA). KA (1 µg KA in 2.5 µl PBS, Sigma) alone or in 
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combination with VP1.14 (2.5 μg in 2.5 µl PBS) was delivered unilaterally into the left 
hippocampus at a speed of 1 μl/minute using the following coordinates from Bregma:  
posterior, -3.0 mm; lateral, -2.0 mm; depth, 3.5 mm; according to the atlas of Paxinos 
and Watson (Paxinos 1998). The amount of S14 injected was calculated taking into 
account the distribution volume of 1ml and a concentration of 4μM, which is effective 
in the in vitro experiments (Supplementary Figure 1). This concentration of VP1.14 did 
not significantly alter cell viability (Supplementary Figure 2). Control animals of the 
same age were injected with vehicle. Rats were then housed individually to recover. 
 
1.4. Immunohistochemistry 
Seventy two hours after stereotaxic injection, the animals were anesthetized and 
perfused transcardially with 4% paraformaldehyde solution. The brains were removed, 
post-fixed in the same solution at 4ºC overnight, cryoprotected in the paraformaldehyde 
solution containing 30% sucrose, frozen, and coronal sections (30 μm) were obtained in 
a cryostat. Free floating sections were stained with cresyl violet (Nissl staining) and 
Fluoro-Jade B or processed for immunohistochemistry using the diaminobenzidine 
method as previously described (Cortes-Canteli et al. 2008). The following antibodies 
were used: mouse monoclonal anti- CD11b (clone OX-42, Serotec; 1:200), mouse 
monoclonal anti-GFAP (Sigma; 1:400), and mouse monoclonal anti-NeuN (clone A60, 
Millipore; 1:200). The slides were examined with a Nikon eclipse 90i microscope. 
Neuronal integrity and the extent of gliosis were quantified as previously described 
(Morales-Garcia et al. 2009). The number of neurons Nissl-, NeuN-, or Fluoro Jade-B-
positive cells in the CA1 and CA3 areas of the hippocampus, was assessed by counting 
five independent well-defined high-magnification (400X) fields per animal using 
computer-assisted image analySIS software and NIS-Elements BR 3.0 (Soft Imaging 
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System). The extent of microgliosis was quantified by counting the number of CD-11b-
positive cells in five independent well defined high-magnification (400X) fields per 
animal, as described above. Astrogliosis was evaluated in sections immunostained with 
GFAP and using two different parameters: number of activated cells, based on the 
calculation of highly immunostained cell body profiles, and immunosignal intensity, 
based on the measurement of optical density. Individual cell bodies were manually 
traced, and their mean staining intensity was normalized against the background of the 
respective section, defined as tissue devoid of specific immunostaining. The procedure 
resulted in arbitrary values on a scale from 1 (background staining) to 256. 
 
1.5. Immunocytochemistry 
At the end of the treatment period, primary astrocyte cultures, grown on glass cover-
slips, were washed with PBS, fixed for 30 min with 4% paraformaldehyde at 25°C and 
permeabilized with 0.1% Triton X-100 for 30 min at 37°C. After 1 h incubation with 
the corresponding primary antibody cells were washed with PBS and incubated with an 
Alexa-labeled secondary antibody (Invitrogen; 1:400) for 45 min at 37°C. Images were 
acquired using a LSM710 confocal microscope (Zeiss), with a 350 nm diode laser to 
excite DAPI (4, 6-diamidino-2-phenylindole) and a 488 laser to excite Alexa 488. 
Confocal microscope settings were adjusted to produce the optimum signal to noise 
ratio. To compare fluorescence signals from different preparations, settings were fixed 
for all samples within the same analysis. The following antibodies were used: goat anti-
interleukin-6 (anti-IL-6, Santa Cruz Biotechnology; 1:200) and goat anti-
cyclooxygenase type 2 (anti-COX-2, Santa Cruz Biotechnology; 1:200). A quantitative 
analysis of labeled cells was undertaken using the image analySIS software and 
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normalized to total nuclei. Areas to be counted were traced at high power (400X), and at 
least five different counting fields were selected at random per culture. 
 
1.6. Nitrite measurements 
To measure the levels of nitrite (NO2–) in astrocyte cultures after treatments, 
supernatants were collected and mixed with an equal volume of Griess reagent (Sigma-
Aldrich).Samples were incubated for 15 min at room temperature and the absorbance 
was measured at 540 nm on a microplate reader. 
 
1.7. Cell viability assay 
For assessment of cell viability, a modified colorimetric MTT assay (Mosmann 1983) 
was used. This method is based on the ability of viable cells to reduce MTT (yellow 
solution) to formazan (dark blue crystals). After 24 h of treatment, HT22 cells were 
incubated with MTT solution (0.5 mg/ml PBS; Sigma-Aldrich) for 1 h at 37ºC, then 
aspirated and dimethyl sulfoxide was added and mixed thoroughly to dissolve dark blue 
crystals. The absorbance was read at 595 nm (wave long reference at 650 nm) with a 
microplate reader (Thermolab). The cell viability was expressed as a percentage relative 
to the control cells (cells not treated with glutamate). 
 
1.8. Western blot 
Proteins were isolated from cell cultures by standard methods. After electrophoresis, 
proteins were transferred to nitrocellulose membranes (Protran, Whatman) and blots 
were probed with the indicated primary antibodies, as previously described (Cortes-
Canteli et al. 2004). The primary antibodies used were the following: rabbit monoclonal 
anti-pGSK3 (Cell Signaling Technology) and mouse monoclonal anti-GSK-3 (BD 
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Bioscience) and the secondary peroxidase-conjugated mouse anti-rabbit and rabbit anti-
mouse antibodies respectively were from Jackson Immunoresearch. Quantification 
analysis was performed using the Scion Image software. Values in the Figure are the 
mean of at least three independent experiments corresponding to three different 
samples. 
 
1.9. Statistical Determinations 
Statistical comparisons for significance among different groups of animals were 
performed by ANOVA followed by Newman-Keuls’test for multiple comparisons. 
Student t test was used to analyze statistical differences between cells. Differences were 
considered statistically significant at p<0.05. Data are given as the mean ± SEM of at 
least five different animals per group or three different experiments in vitro.  
 
2. Results 
2.1. Neuroprotective role of VP1.14 after excitotoxic brain injury 
We studied the effect of VP1.14 in an established excitotoxic model in vivo. Adult rats 
received intrahippocampal injections of vehicle (PBS), KA or KA plus VP1.14 and 
animals were killed 72 h after injection. We first evaluated the extent of cell loss in the 
CA1 and CA3 regions of the hippocampus by Nissl staining (Fig 2A). We observed an 
almost total preservation of CA1 neurons in VP1.14-injected rats, compared with more 
than 80% loss in KA-injected animals (Fig. 2B). Regarding the CA3 region 
approximately 30% of the neurons survived in the VP1.14-injected animals. We further 
analyzed the extend of pyramidal neuronal cell death after excitotoxicity by staining 
with anti-NeuN antibody to detect surviving neurons, or with Fluoro-Jade B (Schmued 
et al. 1997) to detect degenerating neurons (Fig 3). The VP1.14-injected rats exhibited 
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significantly less damage in the CA1 and CA3 regions compared with the KA-injected 
rats, indeed there was no neuronal loss in CA1 and only a 30% loss in NeuN + cells in 
CA3 in contrast with a loss of 20 and 43% respectively in CA1 and CA3 of KA treated 
rats (Fig. 3A, C). In agreement with these results, VP1.14-treated animals presented a 
diminished Fluoro-Jade B fluorescence in these regions of the hippocampus 72 h after 
KA injection (Fig 3B, D), compared with the strong damage observed in KA-injected 
rats. 
 
2.2. VP1.14 treatment inhibits glial activation 
One of the events that take place in the hippocampus following excitotoxic injury is the 
sequential activation of microglia and astroglia. Microglial and astrocyte cells are 
considered to be key players in the induction of the neuronal damage following 
excitotoxic injury. Analysis of hippocampal sections revealed the expected 
accumulation of GFAP-positive astrocytes, 72 hours after KA injection, relative to 
vehicle-injected animals (Figure 4A). This increase in GFAP immunoreactivity was 
mainly detected in the CA1 and CA3 regions of the hippocampus. By contrast, VP1.14-
treated rats displayed much less staining for GFAP, indicating a reduced astroglial 
response to KA-induced injury.  Quantification of the data revealed a 2.4-fold decrease 
in the number of strongly-stained GFAP+ astrocytes in the CA1 and CA3 regions. We 
also detected a similar decrease on GFAP staining intensity (Fig. 4C, D). 
 In addition, the evaluation of CD11b staining for microglial infiltration revealed a 
considerably larger response in KA-injected rats than that found in those animals treated 
with VP1.14 (Fig. 4B). Quantitative studies (Fig. 4E) showed a 4-fold decrease in the 
number of CD11b-positive cells in the CA1 and CA3 of VP1.14-treated rats, compared 
with KA-injected rats 
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2.3. VP1.14 protects hippocampal neurons from cell death and inhibits inflammatory 
activation of astrocyte cultures 
We next examined the effect of VP1.14 in vitro on cell death in the murine hippocampal 
cell line HT22. As shown in Figure 5A, glutamate treatment resulted in a loss of cell 
viability, as assessed by a decline in MTT, as compared with control untreated cells. 
Incubation with VP1.14 or BRL-50481, a well-known inhibitor of PDE7, caused a 
neuroprotective effect against glutamate-induced injury, as shown by an elevation in the 
cell viability of 20% and 27%, respectively (Fig 5A). 
 
 The potential anti-inflammatory activity of VP1.14 was tested by studying nitrite 
production and the expression levels of two pro-inflammatory agents, IL-6 and COX-2, 
in primary cultures of astrocytes treated with glutamate or lipopolysaccharide (LPS). To 
measure nitrite production, astrocytes were incubated with VP1.14 or BRL-50481 for 2 
h, and then cells were cultured for another 24 h with LPS. As shown in Fig. 5B, LPS 
treatment resulted in a 3.2-fold increase in the concentration of nitrites in the culture 
medium, which was significantly prevented by treatment with VP1.14 and BRL-50481. 
  
To further evaluate the role of PDE7 inhibition in the inflammatory response in neural 
tissues, we tested the effects of VP1.14 and BRL-50481 on the expression levels of IL-6 
and COX-2 in astrocyte cultures treated with glutamate (Fig. 6A,B) or LPS (Fig. 6 
C,D). To this end, we performed immunofluorescence analysis followed by confocal 
microscopy. In basal conditions, IL-6 and COX-2 levels were barely detectable in 
astrocyte cultures, and their content was significantly induced after glutamate or LPS 
treatment. However, the number of astrocytes expressing IL-6 was significantly reduced 
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(7.8- and 2.3- fold) in cultures treated with glutamate plus VP1.14 or BRL-50481, 
respectively. Similar results were observed in those cultures treated with LPS plus 
VP1.14 or BRL-50481. In parallel, we also observed a significant reduction in the 
number of cells expressing the pro-inflammatory enzyme COX-2 in those cultures 
treated with VP1.14 or BRL-50481, compared to glutamate-treated cultures. The effects 
of VP1.14 and BRL-50481 were not caused by a loss of cell viability, because the 24 h 
exposure of astrocyte cells to these compounds did not modify cell viability 
(Supplementary Figure 2). 
 
2.4. VP1.14 phosphorylates glycogen synthase kinase-3 (GSK-3) 
It has been previously shown a synergistic interaction between PDE4, another cAMP 
hydrolyzing enzyme, and GSK-3 (Lipina et al. 2012). We then analyzed whether 
VP1.14 could phosphorylate, and in consequence inactivate, GSK-3. As shown in 
Figure 7, VP1.14 treatment of astrocytes results in an enhancement of GSK-3 
phosphorylation in serine9. Treatment of cells with H89 (a protein kinase A inhibitor 
(PKA)) partially reversed GSK-3 phosphorylation, suggesting that this phosphorylation 
was mediated, at least in part, by an activation of PKA. 
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3. Discussion 
Here, we have shown that a novel thiadiazole derivative, VP1.14, which is a dual 
inhibitor of PDE7 and GSK-3, prevented both the glial activation and the neuronal cell 
death that occur in the hippocampus as a consequence of an excitotoxic insult. These 
results are further supported by in vitro studies directly demonstrating the anti-
inflammatory and neuroprotective effects of this compound. These results establish 
PDE7 as a factor involved in the development of excitotoxic injury and suggest a role 
for PDE7 as a novel target for treatment of brain disorders such as epilepsy, ischemia, 
and neurodegenerative diseases, in which excitotoxicity is involved (Coyle & 
Puttfarcken 1993, Guo et al. 1999, Lynch & Dawson 1994, Hossmann 1994). 
 
These data are in agreement with recent reports showing a neuroprotective role of PDE7 
inhibition. Our laboratory has recently demonstrated an important neuroprotective role 
of PDE7 inhibition by quinazolines compounds in in vitro and in vivo models of stroke 
and Parkinson disease (Palomo et al. 2012, Morales-Garcia et al. 2011). Also, very 
recently Paterniti et al. have shown that inhibition of this enzyme by different 
compounds (quinazolines and 5-imino-1,2,4-thiadizoles) significantly reduced the 
degree of spinal cord inflammation and tissue injury in a model of spinal cord injury 
(Paterniti et al. 2011).  
 
Glutamate is the driver of the excitotoxic process (Uryu et al. 2002). Although 
glutamate plays a central role in excitatory neurotransmission, alterations in glutamate 
homeostasis, with an excessive glutamate activity, can have significant repercussions on 
neurons through the generation of neurotoxic and excitotoxic cascades (Mody & 
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MacDonald 1995). (Dawson & Dawson 1996). Intrahippocampal injection of the 
excitotoxin kainic acid in rats is a common and well-characterized model of 
excitotoxicity. This treatment induces selective degeneration of hippocampal CA1 and 
CA3 pyramidal neurons and a significant fraction of dentate hilar neurons (Nadler et al. 
1980, Shetty & Turner 1996). Our results show that dual GSK-3 and PDE7 inhibition 
clearly protects hippocampal neurons from KA-induced injury. In addition, VP1.14 
protected the HT22 hippocampal neuronal cell line from glutamate injury. 
 
One of the events associated to the neurodegeneration that takes place in several brain 
disorders is an inflammatory response, which is characterized by a reactive gliosis. 
Activation of glial cells leads to the production of toxic substances, including the 
enzyme COX-2 and cytokines such as IL1β, IL-6, and TNF-α, that further damage 
neurons, leading to a cycle of inflammatory damage that ultimately worsens the 
progression of the disease (Dawson & Dawson 1996). This view is further supported by 
epidemiologic data showing that long-term treatment with non-steroidal anti-
inflammatory drugs may protect against Alzheimer disease and Parkinson disease 
(Townsend & Pratico 2005, Chen et al. 2003, Hald & Lotharius 2005). Unfortunately, 
current therapies directed to treatment of brain injury do not address this 
neuroinflammation process.  
 
The results presented here, demonstrate that VP1.14 treatment significantly reduces the 
accumulation of reactive astrocites and microglia in the hippocampus and the 
production of COX-2 and IL-6 induced by glutamate and LPS treatment in primary 
astrocytes. In this regard, our group has shown that the thiadiazolidinone (TDZD) 
compounds, which are GSK-3 inhibitors and also activators of the nuclear receptor 
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PPARγ, also show anti-inflammatory and neuroprotective effects in KA induced injury 
(Luna-Medina et al. 2005, Luna-Medina et al. 2007b). 
 
Our results showing a phosphorylation of GSK-3 in serine9 by VP1.14 suggest that the 
observed effects of this compound could also be mediated by an inhibition of GSK-3. In 
this regard it has been previously shown that an inhibitor of PDE4B and a GSK-3 
blocker synergize to produce antipsychotic effects on the Disrupted-In-Squizophrenia-
1-L100P genetic model (Lipina et al. 2012). In addition, our group has recently 
demonstrated that the novel family of 5-imino-1,2,4-thiadiazoles is able to inhibit GSK-
3 in a substrate competitive manner (Palomo et al. 2012). Thus, our results indicate that 
VP1.14 could be acting through an inhibition of PDE7, which elevates cAMP levels, 
together with an inactivation of GSK-3 by a direct inhibition of this enzyme as well as 
by an inactivation through phosphorylation on Ser9 by the PKA enzyme. The fact that 
VP1.14 is targeting both PDE7 and GSK-3 enzymes may underlies the strong 
neuroprotective and anti-inflammatory activities of this compound. 
 
In summary, our results demonstrate that a novel 5-imino-1,2,4-thiadiazole compound, 
through inhibition of PDE7 and GSK-3 enzymes, has a significant neuroprotective and 
anti-inflammatory effect in KA-injected rats, a well-characterized model of 
excitotoxicity. In addition, this inhibition diminished the induction of pro-inflammatory 
agents after glutamate or LPS treatment in vitro. Hence, PDE7 may be a potential new 
therapeutic target deserving further attention for the treatment of acute brain injury and 
neurodegenerative diseases, where excitotoxic and inflammatory processes are 
involved. 
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Figure legends 
Figure 1. Chemical Structure of the 5-imino-1,2,4-thiadiazole VP1.14.  
 
Figure 2. Neuroprotective effects of VP1.14 on KA-induced neuronal loss in the 
hippocampus. Rats were injected with vehicle, KA, or KA plus VP1.14 and the different 
groups were sacrificed 72 h post-injection. (A) Representative coronal sections stained 
with Nissl. Scale bars, 100 μm. (B) Quantification of the number of neurons stained by 
Nissl in the CA1 and CA3 regions of hippocampus. Values represent the mean ± SEM 
from at least five different animals and two different sections per animal. *** p ≤ 0.001 
vs KA injected rats.  
 
Figure 3. VP1.14 protects hippocampal neurons from excitotoxic brain damage. Rats 
were injected with vehicle, KA, or KA plus VP1.14 and the different groups were 
sacrificed 72 h post-injection. Coronal sections were stained with anti-NeuN antibody 
(A) and Fluoro-Jade B (B). Representative images are shown.  Scale bars, 100 μm. 
Quantification of neurons stained with anti-NeuN specific antibody (C) and Fluoro-Jade 
B (D) in the CA1 and CA3 regions of hippocampus. Values represent the mean ± SEM 
from at least five different animals and two different sections per animal. * p ≤ 0.05 , ** 
p ≤ 0.01 vs KA injected rats. 
 
Figure 4. VP1.14 decreases glial activation induced by KA in the CA1 and CA3 
regions of the hippocampus. Rats were injected with vehicle, KA, or KA plus VP1.14 
and the different groups were sacrificed 72 h post-injection. Coronal sections were 
stained with mouse monoclonal antibodies directed against either GFAP (A) or CD11b 
(B) to detect astrocytes or microglial cells, respectively. Representative images are 
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shown. Scale bars, 100 μm. (C, D) Quantification of the number of reactive astrocytes 
and their immunostaining intensity. (E) Quantification of the number of reactive 
microglial cells. Values represent the mean ± SEM from at least five different animals 
and two different sections per animal. * p ≤ 0.05 , ** p ≤ 0.01, *** p ≤ 0.001 vs KA 
injected rats.  
 
Figure 5. VP1.14 protects HT22 neuronal cultures and reduces nitrite production in 
astrocyte cultures after an excitotoxic or pro-inflammatory injury. (A) HT22 cells were 
treated for 24h with glutamate (3 mM) in presence or absence of VP1.14 (3 µM) or 
BRL-50481 (30 µM). Cell viability was measured by the MTT assay. Values represent 
the mean ± SEM of six replications in at least two different experiments. * p ≤ 0.05 vs 
glutamate treated cells. (B) Nitrite production was measured by the Griess reaction in 
the supernatant of astrocytes that were treated for 24h with LPS (10 µg/ml) in the 
presence or absence of VP1.14 (3 µM) or BRL-50481 (30 µM). Values represent the 
mean ± SEM from six replications in at least two different experiments. * p ≤ 0.05 vs 
LPS treated cells. 
 
Figure 6. VP1.14 inhibits the expression of pro-inflammatory mediators in astrocyte 
cultures after LPS treatment. Rat primary astrocytes cultures were treated for 24 h with 
glutamate (500 µM) (A) or LPS (10 µg/ml) (C) in presence or absence of VP1.14 (3 
µM) and BRL-50481 (30 µM). The expression of IL-6 and COX-2 were evaluated by 
immunofluorescence analysis and confocal microscopy using specific antibodies, as 
described in Materials and Methods. Representative confocal images are shown. Scale 
bar, 10 µm. Nuclei were counterstained with DAPI (blue). (B, D) Quantification of 
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labeled cells. Values represent the mean ± SEM of at least two different experiments * p 
≤ 0.05, ** p ≤ 0.01 vs glutamate or LPS treated cells. 
 
Figure 7. VP1.14 phosphorylates GSK-3 enzyme. (A) Representative Western blot 
showing an increase in p-GSK-3 in primary cultures of astrocytes treated with VP1.14  
or VP1.14 plus H89 for 30 minutes. (B) Quantification analysis of three different blots. 
**p≤ 0.01 vs control cells, #p ≤ 0.05 vs VP1.14 treated cells. 
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